Click
on links on the left for bibliographic information related to a
specific research area
2013
Cholesterol
and atherosclerosis: Modulation
by estrogen
M. Barton
Curr
Opin Lipidol (in
press) 2013
Childhood
obesity: preventing today's children from becoming tomorrow's
patients
M. Barton
IFAVA
Scientific Newsletter 75,
1, 2013
Endothelin
in coronary artery disease and myocardial infarction
T.M. Kolettis, M. Barton, D. Langleben, Y.
Matsumura
Cardiol
Rev (epub
ehead of print Feb 21) 2013
Themed section: Endothelin
A.P.
Davenport, M. Barton
Br
J Pharmacol 168,
269-272, 2013
2012
Endothelin XII - Editorial
M. Barton, M. Yanagisawa, P.M. Vanhoutte, T.
Masaki
Life
Sci 91,
449-451, 2012
The Twelfth International Conference on Endothelin
(ET-12), Cambridge 2011
M.
Barton, A.P. Davenport
Life
Sci 91,
462-465, 2012
The First Tomoh Masaki Award
(2011)
M.
Barton, N. Emoto, T. Miyauchi
Life
Sci 91,
466-469, 2012
Clinical trials with endothelin receptor
antagonists: What went wrong and where can we
improve?
D.E. Kohan, J.G. Cleland, L.J. Rubin, D. Theodorescu, M.
Barton
Life
Sci 91,
528-539, 2012
The future of endothelin research: scientific
mentoring and beyond
M. Barton, D.M. Pollock
Life
Sci 91,
470-474, 2012
GPER regulates endothelin-dependent vascular tone
and intracellular calcium
M.R.
Meyer, A.S. Field, N.L. Kanagy, M. Barton, E.R.
Prossnitz
Life
Sci 91,
623-627, 2012
Testosterone and secondary hypertension: New pieces
to the puzzle
M. Barton, E.R. Prossnitz, M.R. Meyer
Hypertension
59,
1011-1103, 2012
Position paper: The membrane estrogen receptor GPER
- clues and questions
M. Barton
Steroids
77,
925-242, 2012
Endothelin and the podocyte
M. Barton, P.L. Tharaux
Clin
Kidney J 5,
17-27,
2012
Endothelin receptor antagonists in cardiovascular
medicine: Challenges and opportunities
M.
Barton
In:
Translational Vascular Medicine (D.
Abraham, Ed) Springer London, 231-259, 2012
Deletion of the G protein-coupled estrogen receptor
increases endothelial vasoconstriction
M.R. Meyer, K. Amann, A.S. Field, C. Hu, H.J. Hathyway, N.L.
Kanagy, M.K. Walker, M. Barton, E.R. Prossnitz
Hypertension
59,
507-512, 2012
Childhood obesity: a life-long health
risk
M. Barton
Acta
Pharmacol Sin 33,
189-193, 2012
Obesity and risk of vascular disease: Importance of
endothelium-dependent vasoconstriction
M.
Barton, O. Baretella, M.R. Meyer
Br
J Pharmacol 165,
591-602, 2012
2011
The G protein-coupled estrogen receptor GPER in
physiology and disease
E.R. Prossnitz, M. Barton
Nature
Rev Endocrinol 7,
715-726, 2011
Endothelin in renal physiology and
disease
Contrib
Nephrol 172
(M. Barton, D.E. Kohan, Eds), Karger, Basel, 1-266,
2011
The G protein-coupled estrogen receptor GPER/GPR30
as a regulator of cardiovascular function
M.R. Meyer, E.R. Prossnitz, M. Barton
Vascul
Pharmacol 55,
17-25, 2011
Endothelin antagonists in clinical trials: Lessons
learned
M. Barton, D.E. Kohan
Contrib
Nephrol 172,
255-260, 2011
Endothelin and podocyte injury in chronic kidney
disease
C. Fligny, M. Barton, P.L. Tharaux
Contrib
Nephrol 172,
120-138, 2011
Endothelin antagonism and reversal of proteinuric
renal disease in humans
M. Barton
Contrib
Nephrol 172,
210-222, 2011
Obesity, insulin resistance and diabetes: sex
differences and role of estrogens receptors
M.R. Meyer, D.J. Clegg, E.R. Prossnitz, M.
Barton
Acta
Physiol (Oxf) 203,
259-269, 2011
GPER/GPR30 and regulation of vascular tone and blood
pressure
M.R. Meyer, E.R. Prossnitz, M. Barton
Immunol
Endocr Metab Agents Med Chem 4,
255-261, 2011
Estrogen-independent activation of estrogen
receptors
M.
Barton, M.R. Meyer, E.R. Prossnitz
Hypertension
57,
1056-1057, 2011
The discovery of endothelium-dependent contraction:
the legacy of Paul M. Vanhoutte
M. Barton
Pharmacol
Res 63,
455-462, 2011
2010
Therapeutic potential of endothelin receptor
antagonists for chronic proteinuric renal disease in
humans
M. Barton
Biochim
Biophys Acta 1802,
1203-1213, 2010
Obesity and aging: determinants of endothelial cell
dysfunction and atherosclerosis
M. Barton
Pflügers
Arch Eur J Physiol 460,
825-837, 2010
Übergewicht und kardiovaskuläres Risiko: Neues zu
Pathogenese und Therapie
M.R. Meyer, C.A. Meier
Swiss
Medical Forum 10,
358-362, 2010
Anti-inflammatory effects of endothelin receptor
antagonists and their importance for treating human
disease
M. Barton, P.C. Nett, K. Amann, M.M.
Teixeira
Front
Cardiovasc Drug Discov 1,
236-258, 2010
Dilation of epicardial coronary arteries by the G
protein-coupled estrogen receptor agonists G-1 and ICI
182,780
M.R. Meyer, O. Baretella, E.R. Prossnitz, M.
Barton
Pharmacology
86,
58-64, 2010
Lung cancer and hormone replacement
therapy
M. Barton, M.R. Meyer, J.L. Bolton, E.R.
Prossnitz
Lancet
375,
117-118, 2010
2009
Postmenopausal
hypertension: Mechanisms and therapy
M. Barton, M.R. Meyer
Hypertension
54,
11-18, 2009
ERα,
ERβ, and gpER: novel aspects of estrogen receptor signaling in
atherosclerosis
M.R. Meyer, M. Barton
Cardiovasc Res 83,
605-610, 2009
Non-genomic
regulation of vascular cell function and growth by
estrogen
M.R. Meyer, E. Haas, E.R. Prossnitz, M.
Barton
Mol
Cell Endocrinol 308,
9-16, 2009
Signaling,
physiological functions and clinical relevance of the G
protein-coupled estrogen receptor GPER
E.R. Prossnitz, M. Barton
Prostaglandins
Other Lipid Mediat 89,
89-97, 2009
Regulatory role of G protein coupled estrogen
receptor for vascular function and obesity
E. Haas, I. Bhattacharya, E. Brailoiu, M. Damjanovic, G.C.
Brailoiu, X. Gao, L. Mueller-Guerre, A. Gut,
R. Minotti, M.R. Meyer, K. Amann, E. Ammann, A. Perez-Dominguez, M.
Genoni, D.J. Clegg, N.J. Dun,
T.C. Resta, E.R. Prossnitz, M. Barton
Circ
Res 104,
288-291, 2009
Getting
radical about obesity: new links between fat and heart
disease
M. Barton, E. Haas, I. Bhattacharya
Arterioscler
Thromb Vasc Biol 29,
447-448, 2009
Morbus
Addison bei metastasierendem Bronchuskarzinom
M.R. Meyer, A. Ciurea-Löchel, M. Häfner, B.
Senn
Swiss
Medical Forum 9,
487-488, 2009
2008
Endothelin
- Twenty years from discovery to therapy
M. Barton, M. Yanagisawa
Can
J Physiol Pharmacol 86,
485-498, 2008
Reversal
of proteinuric renal disease and the emerging role of
endothelin
M. Barton
Nature
Clin Pract Nephrol 4,
490-498, 2008
Need
for research on estrogen function: importance for postmenopausal
hormone therapy and atherosclerosis
M.R. Meyer, E. Haas, M. Barton
Gend
Med 5
(Suppl. A), S19-S33, 2008
Regional
heterogeneity of functional changes in conduit arteries after
high-fat diet
I. Bhattacharya, A.L. Mundy, C.C. Widmer, M. Kretz, M.
Barton
Obesity
(Silver Spring) 16,
743-748, 2008
Schwere
Verhaltensstörung mit organischer Ursache
M.R. Meyer, B. Rüegger-Frey, N. Nikolic, I.
Bopp-Kistler
Praxis
(Bern 1994) 97,
1137-1141, 2008
Fat
intake and cardiovascular response
M.
Damjanovic, M. Barton
Curr
Hypertens Rep 10,
25-31 2008
2007
Inflammation
and atherosclerosis
M. Barton, R. Minotti, E. Haas
Circ
Res 101,
750-751, 2007
Hormone
replacement therapy and atherosclerosis in postmenopausal women:
does aging limit therapeutic benefits?
M. Barton, M.R. Meyer, E. Haas
Arterioscler
Thromb Vasc Biol 27,
1669-1672, 2007
WISDOM
trial, postmenopausal hormone replacement and cardiovascular
events: Why it is still not wise to use equine
estrogens
M. Barton, M.R.Meyer, I. Bhattacharya, E. Haas
Br
Med J Rapid
Response, e-pub August 28, 2007
Atherosklerotische Gefässerkrankungen
und Stickstoffmonoxid (NO): Die wachsende Bedeutung von hoher
Lebenserwartung
und
Übergewicht für die Klinik
M. Husmann, M. Keller, M. Barton
Swiss
Medical Forum 50,
1008-1011, 2007
Distinct
roles of estrogen receptors
α
and
β
mediating acute vasodilatation of epicardial coronary
arteries
T. Traupe, C.D. Stettler, H. Li, E. Haas, I. Bhattacharya, R.
Minotti, M. Barton
Hypertension
49,
1364-1370, 2007
Differential
effects of 17β-estradiol on function and expression of estrogen
receptor α, estrogen receptor β, and GPR30 in arteries and veins of
patients with atherosclerosis
E. Haas, M.R. Meyer, U. Schurr, I. Bhattacharya, R. Minotti, H.H.
Nguyen, A. Heigl, M. Lachat, M. Genoni, M.
Barton
Hypertension
49,
1358-1363, 2007
Effects
of obesity on mortality in patients with unstable angina or non
ST-elevation myocardial infarction
M. Barton, M. Husmann
Eur
Heart J 28,
2950, 2007
Impaired
vascular function in normoglycemic mice prone to autoimmune
diabetes: Role of nitric oxide
T. Traupe, P.C. Nett, B. Frank, L. Tornillo, R. Hofmann-Lehmann,
L.M. Terracciano, M. Barton
Eur
J Pharmacol 557,161-167,
2007
Artériopathies
athérosclérotique et monoxyde d’azote (NO) : l’importance
clinique d’une espérance de vie plus longue et
l’obésité
M. Husmann, M. Keller, M. Barton
Forum
Médical Suisse 50,
1008-1011, 2007
Vaskuläre
Interaktion zwischen Insulin und LDL Cholesterin
E. Haas, R. Minotti, C. Raselli, A. Hoehn, M.
Barton
Dtsch
Med Wochensch 132,
20, 2007
Endothelin
stimulates vascular hydroxyl radical formation: effect of
obesity
A.L. Mundy, E. Haas, I. Bhattacharya, C.C. Widmer, M. Kretz, K.
Baumann, M. Barton
Am
J Physiol Regul Integr Comp Physiol 293,
R2218-R2224, 2007
Fat
intake modifies vascular responsiveness and receptor expression of
vasoconstrictors: Implications for diet-induced
obesity
A.L. Mundy, E. Haas, I. Bhattacharya, C.C. Widmer, M. Kretz, R.
Hofmann-Lehmann, R. Minotti, M. Barton
Cardiovasc
Res 73,
368-375, 2007
Therapeutic
potential of direct thrombin inhibitors for atherosclerotic
vascular disease
M. Husmann, M. Barton
Expert
Opin Investig Drugs 16,
563-567, 2007
Oral direct thrombin inhibitors and
atherosclerosis
M. Husmann, M. Barton
International
Atherosclerosis Society ,
e-pub Sept 3, 2007
Antioxidant
activity and sex differences of acute vascular effects of
amiodarone in advanced atherosclerosis
T. Traupe, M. Keller, E. Fojtu, I. Bhattacharya, M. Lang, H.R. Ha,
W. Jochum, A.L. Mundy, M. Barton
J
Cardiovasc Pharmacol 50,
578-584, 2007
2006
Gender
differences of cardiovascular disease: new perspectives for
estrogen receptor signaling
M.R.
Meyer, E. Haas, M. Barton
Hypertension
47,
1019-26, 2006
Transcriptional
regulation of vascular bone morphogenetic protein by endothelin
receptors in early autoimmune diabetes mellitus
P.C. Nett, J. Ortmann, J. Celeiro, E. Haas, R. Hofmann-Lehmann, L.
Tornillo, L.M. Terraciano, M. Barton
Life
Sci 78,
2213-2218, 2006
Recent
developments on endothelin antagonists as immunomodulatory drugs -
from infection to transplantation medicine.
P.C. Nett, M.M. Teixeira, D. Candinas, M.
Barton
Recent
Pat Cardiovasc Drug Discov 1,
233-244, 2006
Role
of endothelin receptors for renal protection and survival in
hypertension. Waiting for clinical trials
M. Barton, J.J. Mullins, M.A. Bailey, M.
Kretzler
Hypertension
48,
834-837, 2006
Endothelin
ETA
receptor blockade with darusentan increases sodium and potassium
excretion in aging rats
T. Traupe, J. Ortmann, E. Haas, K. Münter, N. Parekh, R.
Hofmann-Lehmann, K. Baumann, M. Barton
J
Cardiovasc Pharmacol 47,
456-462, 2006
Beneficial
cardiovascular effects of endothelin ETA
receptor blockade in established long-term heart failure after
myocardial infarction
D. Vetter, S.G. Shaw, R.P. Brandes, K. Münter, W. Vetter, M.
Barton
Exp
Biol Med (Maywood) 231,
857-60, 2006
Upregulation
of endothelin converting enzyme-1 in host liver during chronic
cardiac allograft rejection
T. Lattmann, J. Ortmann, S. Horber, S.G. Shaw, M. Hein, M.
Barton
Exp
Biol Med (Maywood) 231,
899-901, 2006
Long-term
effects of endovascular angioplasty on orthostatic vasocutaneous
autoregulation in patients with peripheral atherosclerosis
M.J. Husmann, M. Barton, V. Jacomella, A. Silvestro, B.R.
Amann-Vesti
J
Vasc Surg 44,
993-997, 2006
Downregulation
of renal endothelin-converting enzyme 2 expression in early
autoimmune diabetes
J.
Ortmann, P.C. Nett, J. Celeiro, R. Hofmann-Lehmann, L. Tornillo,
L.M. Terraciano, M. Barton
Exp
Biol Med (Maywood) 231,
1030-1033, 2006
Early
aging and anatomic heterogeneity determine cyclooxygenase-mediated
vasoconstriction to angiotensin II in mice
M. Kretz, A.L. Mundy, C.C. Widmer, M. Barton
J
Cardiovasc Pharmacol 48,
30-33, 2006
Rapid
endocytosis of copper-zinc superoxide dismutase into human
endothelial cells: role for its vascular
activity
E.R. Waelti, M. Barton
Pharmacology
78,
198-201, 2006
Upregulation
of endothelin receptor B in human endothelial cells by low-density
lipoproteins
G. Muller, R.A. Catar, B. Niemann, M. Barton, L. Kneels, M. Wendel,
H. Morawietz
Exp
Biol Med (Maywood) 231,
766-771, 2006
Life
Sci 78,
2213-2218, 2006
Marked
heterogeneity of endothelin-mediated contractility and contraction
dynamics in mouse renal and femoral arteries
C.C. Widmer, A.L. Mundy, M. Kretz, M. Barton
Exp
Biol Med (Maywood) 231,
777-781, 2006
Postural
effects on interstitial fluid pressure in humans
M.J. Husmann, M. Barton, B.R. Amann-Vesti, U.K.
Franzeck
J
Vasc Res 43,
321-326, 2006
2005
Ageing
as a determinant of renal and vascular disease: role of endothelial
factors
M. Barton
Nephrol
Dial Transplant 20,
485-490, 2005
Anatomically
distinct activation of endothelin-3 and the L-arginine/nitric oxide
pathway in the kidney with advanced aging
T. Lattmann, S. Shaw, K. Münter, W. Vetter, M.
Barton
Biochem
Biophys Res Commun 327,
234-241, 2005
Ageing
as a determinant of renal and vascular disease: role of endothelial
factors
M. Barton
Nephrol
Dial Transplant 20,
485-490, 2005
Aging
and biomedicine 2005: Where should we go from
here?
M. Barton
Cardiovasc
Res 66,
187-189, 2005
Vascular
consequences of menopause and hormone therapy: Importance of timing
of treatment and type of estrogen
R.K. Dubey, B. Imthurn, M. Barton, E.K. Jackson
Cardiovasc
Res 66
, 295- 306, 2005
Endothelin
inhibition delays onset of hyperglycemia and associated vascular
injury in type I diabetes: evidence
for endothelin release by pancreatic islet
β-cells.
J.
Ortmann, P.C. Nett, J. Celeiro, T. Traupe, L. Tornillo, R.
Hofmann-Lehmann, E. Haas, B. Frank, L.M. Terraciano, M.
Barton
Biochem
Biophys Res Commun 334,
689-695, 2005
Native
and oxidized low-density lipoproteins stimulate
endothelin-converting enzyme-1 expression in human endothelial
cells
B. Niemann, S. Rohrbach, R.A. Catar, G. Muller, M. Barton, H.
Morawietz
Biochem
Biophys Res Commun 334,
747-753, 2005
Endothelin
in the microvasculature
M. Barton
In:
Microvascular Research: Biology and Pathobiology
(D.
Shepro, Ed.), Academic
Press,
San Diego, 5-12,
2005
Activation
of pro-inflammatory and anti-inflammatory cytokines in host organs
during chronic allograft rejection:
role of endothelin receptor signaling
T. Lattmann, M. Hein, S. Horber, J. Ortmann, M.M. Teixeira, D.G.
Souza, E. Haas, L. Tornillo, K. Münter, W. Vetter, M.
Barton
Am
J Transplant 5,
1042-1049, 2005
Management
and prevention of obesity-related hypertension
M.
Barton
Renin
Angiotensin System in Cardiovascular Medicine
1,
11-13, 2005
2004
Role
of podocytes for reversal of glomerulosclerosis and proteinuria in
the aging kidney after endothelin inhibition
J. Ortmann, K. Amann, R.P. Brandes, M. Kretzler, K. Münter, N.
Parekh, T. Traupe, M. Lange, T. Lattmann, M.
Barton
Hypertension
44,
974-981, 2004
Protective
Role of ETA
endothelin receptors during the acute phase of Trypanosoma cruzi
infection in rats
E.R.S. Camargos, L.L.V. Rocha, M.A. Rachid, A.P. Almeida, A.J.
Ferreira, A.L. Teixeira-Jr, E. Chiari,
M. Barton, M.M. Teixeira, C.R.S. Machado
Microbes
Infect 6,
650-656, 2004
Amiodarone
acutely inhibits vascular activity of endothelin-converting
enzymes
T. Traupe, M. Lang, J. Ortmann, M. Keller, E. Fojtu, W. Vetter, M.
Barton
J
Cardiovasc Pharmacol 44,
S113-S116, 2004
Upregulation
of vascular ETB
receptor gene expression after chronic ETA
receptor blockade in prediabetic NOD mice
J. Ortmann, T. Traupe, P. Nett, J. Celeiro, R. Hofmann-Lehmann, M.
Lange, W. Vetter, M. Barton
J
Cardiovasc Pharmacol 44,
S105-S108, 2004
In-vivo
interactions of nitric oxide and endothelin
T.
Lattmann, W. Vetter, M. Barton
J
Hypertens 22,
1839-1840, 2004
Protease-activated
receptors and EDHF: the icing on the cake?
T. Traupe and M. Barton
Cardiovasc
Res 61,
645-647, 2004
Einfluss
Postmenopausaler Hormonsubstitution mit konjugierten equinen
Oestrogenen
und Medroxyprogesteronazetat auf das kardiovaskuläre
Risiko
J. Ortmann, W. Vetter, T. Traupe, M. Barton
Schweiz
Rundsch Med Prax 93,
904-914, 2004
2003
Lovastatin
stimulates human vascular smooth muscle cell expression of bone
morphogenetic protein-2,
a potent inhibitor of low-density lipoprotein-stimulated cell
growth
L.
Emmanuele, J. Ortmann, T. Doerflinger, T. Traupe, M.
Barton
Biochem
Biophys Res Commun 302,
67-72, 2003
Obesity-associated
activation of angiotensin and endothelin in the cardiovascular
system
M. Barton, R. Carmona, J. Ortmann, J.E. Krieger, T.
Traupe
Int
J Biochem Cell Biol 35,
826-837, 2003
Cardiovascular
consequences of the obesity pandemic: need for
action
M. Barton, J. Furrer
Exp
Opin Invest Drugs 12,
1757-1759, 2003
Endothelin, hypercholesterolemia and
atherosclerosis
M.
Barton, T. Traupe, C.C. Haudenschild
Coron
Artery Dis 14,
477-490, 2003
Endothelial
therapy of atherosclerosis and its risk factors
T.
Traupe, J. Ortmann, K. Münter, M. Barton
Current
Vasc Pharmacol 1,
111-121, 2003
2002
Obesity
increases prostanoid-mediated vasoconstriction and vascular
thromboxane receptor gene expression
T.
Traupe, M. Lang, W. Goettsch, K. Münter, H. Morawietz, W. Vetter,
M. Barton
J
Hypertens 20,
2239-2245, 2002
Acute
effects of 17β-oestradiol on functional activity of
endothelin-converting enzymes in human arteries and
veins
A. Heigl, M. Lachat, T. Lattmann, T. Lüscher, M.
Barton
Clin
Sci (Lond) 103(S),
438S-441S, 2002
Estrogen
and apoptosis in atherosclerosis
M. Barton, M.M. Kockx
Midlife Health - Current Concepts and Challenges for the Future,
Samioe G, Skouby S, (Eds.). Proceedings of the
5th European Congress on Menopause, Copenhagen, Denmark, July 1-5,
2000
Elsevier
International Congress Series,
81-93, 2002
Postmenopausal
hormone-replacement therapy
M.
Barton, R.K. Dubey
New
Engl J Med 346,
63-65, 2002
Effects
of obesity on endothelium-dependent reactivity during acute nitric
oxide inhibition: modulatory role of endothelin
T. Traupe, L.V. d'Uscio, K. Muenter, H. Morawietz, W. Vetter, M.
Barton
Clin
Sci (Lond) 103
(Suppl. 48), 13S-15S, 2002
Role
of endothelin during experimental Trypanosoma cruzi infection in
rats
E.R.S.
Camargos, C.R.S. Machado, A.L. Teixeira-Jr, L.L.V. Rocha, A.J.
Ferreira, A.P. Almeida, M. Barton, M.M.Teixeira
Clin
Sci (Lond) 103(S),
64S-67S, 2002
Increased
expression of endothelin-converting enzyme-1 in failing human
myocardium
H. Morawietz, W. Goettsch, M. Szibor, M. Barton, S. Shaw, K. Hakim,
H.-R. Zerkowski, J. Holtz
Clin
Sci (Lond) 103(S),
237S-240S, 2002
Chronic
ETA
receptor blockade prevents endothelial dysfunction of small
arteries in apolipoprotein E-deficient mice
L.V. d'Uscio, M. Barton, S. Shaw, T.F. Lüscher
Cardiovasc
Res 53,
487-495, 2002
Native
LDL induces proliferation of human vascular smooth muscle cells via
a redox-mediated activation of ERK1/2 mitogen-activated protein
kinases
R. Locher, R.P. Brandes, W. Vetter, M. Barton
Hypertension
39
(Part 2), 645-50, 2002
Green
tea polyphenols inhibit human vascular smooth muscle cell
proliferation stimulated by native low-density
lipoprotein
R. Locher, L. Emmanuele, P.M. Suter, W. Vetter, M.
Barton
Eur
J Pharmacol 434,
1-7, 2002
Oral
contraceptives and the risk of thrombosis and
atherosclerosis
M. Barton, R.K. Dubey, T. Traupe
Exp
Opin Invest Drugs 11,
329-332, 2002
Chronic
ETA
receptor blockade prevents endothelial dysfunction of small
arteries in apolipoprotein E-deficient mice
L.V. d'Uscio, M. Barton, S. Shaw, T.F. Lüscher
Cardiovasc
Res 53,
487-495, 2002
Angiotensin-converting
enzyme inhibitor therapy prevents upregulation of
endothelin-converting enzyme-1 in failing human
myocardium
H. Morawietz, W. Goettsch, M. Szibor, M. Barton, S. Shaw, K. Hakim,
H.-R. Zerkowski, J. Holtz
Biochem
Biophys Res Commun 295,
1057-61, 2002
Acute
effects of 17β-oestradiol on functional activity of
endothelin-converting enzymes in human arteries and
veins
A.
Heigl, M. Lachat, T. Lattmann, T. Lüscher, M.
Barton
Clin
Sci (Lond) 103(S),
438S-441S, 2002
2001
Postmenopausal
estrogen replacement therapy and atherosclerosis: Can current
compounds provide cardiovascular protection?
M.
Barton
Exp
Opin Invest Drugs 20,
789-809, 2001
Endothelin
receptor blockade and nitric oxide bioactivity
M.
Barton, B. Glodny
Cardiovasc
Res 52,
161-163, 2001
The
therapeutic potential of endothelin receptor antagonists in
cardiovascular disease
M. Barton, W. Kiowski
Curr
Hypertens Rep 3,
322-330, 2001
Endothelin
and cardiac arrhythmias: do endothelin antagonists have therapeutic
potential as antiarrhythmic drugs?
F. Duru, M. Barton, T.F. Lüscher, R. Candinas
Cardiovasc
Res 49,
272-280, 2001
Increased
expression of endothelin-1 and inducible nitric oxide synthase
isoform II in aging arteries in vivo. Implications for
atherosclerosis
W. Goettsch, T. Lattmann, K. Amann, M. Szibor, H. Morawietz, K.
Münter, S.P. Müller, S. Shaw, M. Barton
Biochem
Biophys Res Commun 280,
908-13, 2001
Endothelium
and atherogenesis: endothelial therapy revisited
M. Barton, C.C. Haudenschild
J
Cardiovasc Pharmacol 38
(Suppl. 2), S23-S25, 2001
Increased
expression of endothelin-1 and inducible nitric oxide synthase
isoform II in aging arteries in vivo. Implications for
atherosclerosis
W. Goettsch, T. Lattmann, K. Amann, M. Szibor, H. Morawietz, K.
Münter, S.P. Müller, S. Shaw, M. Barton
Biochem
Biophys Res Commun 280,
908-13, 2001
2000
Obesity
is associated with tissue-specific activation of renal
angiotensin-converting enzyme in vivo.
Evidence for a regulatory role of endothelin
M. Barton, R. Carmona, H. Morawietz, L.V. d'Uscio, W. Goettsch, H.
Hillen, C.C. Haudenschild,
J.E. Krieger, K. Münter, T. Lattmann, T.F. Lüscher, S.
ShawHypertension
35,
329-336, 2000
Endothelin
and endothelin antagonists. Therapeutic considerations for a novel
class of cardiovascular drugs
T.F.
Lüscher, M. Barton
Circulation
102,
2434-2440, 2000
Dysfunctional
renal nitric oxide synthase as a determinant of salt-sensitive
hypertension: mechanisms
of renal artery dysfunction and role of endothelin for vascular
hypertrophy and glomerulosclerosis
M.
Barton, I. Vos, S. Shaw, P. Boer, L.V. d'Uscio, H.-J. Gröne, T.J.
Rabelink, T. Lattmann, P. Moreau, T.F.
Lüscher
J
Am Soc Nephrol 11,
835-846, 2000
Oestrogensubstitutionstherapie
und Arteriosklerose - Pathophysiologie und therapeutische
Implikationen
M. Barton
J
Menopause 7,
12-15, 2000
Hypertension,
diabetes mellitus, hypercholesterolemia and endothelin B
receptor-mediated renal nitric oxide release
M.
Barton, L.V. d'Uscio
Circulation
101;
e228-e229, 2000
Sex
and NO - beyond regulation of vasomotor tone
M. Barton
Cardiovasc
Res 46,
20-23, 2000
Assessment
of coronary flow reserve by contrast-enhanced second harmonic echo
Doppler
R.
Jenni, A. Linka, M. Barton
Circulation
101,
e100, 2000
Deloading
of the left ventricle by ventricular assist device normalizes
increased expression of endothelin ETA
receptors
but not endothelin-converting enzyme-1 in patients with end-stage
heart failure
H. Morawietz, M. Szibor, W. Goettsch, B. Bartling, M. Barton, S.
Shaw, R. Koerfer, H.-R. Zerkowski, J. Holtz
Circulation
102,
III188 -III193, 2000
Doppler
mirror image artifacts mimicking mitral regurgitation in patients
with mechanical bileaflet mitral valve
prostheses
A.Z. Linka, M. Barton, C. Attenhofer Jost, R.
Jenni
Eur
J Echocardiography 1,
138-43, 2000
Ventricular
arrhythmias induced by endothelin-1 or by acute ischemia: a
comparative analysis using three dimensional
mapping
F. Duru, M. Barton, R. Candinas
Cardiovasc
Res 46,
604-605, 2000
Receptor-
and non-receptor-mediated clearance of big-endothelin and
endothelin-1: differential effects of acute and chronic
ETA
receptor blockade
M. Burkhardt, M. Barton, S.G. Shaw
J
Hypertens 18,
273-279, 2000
Endothelial
dysfunction and atherosclerosis: endothelin receptor antagonists as
novel therapeutics
M. Barton
Curr
Hypertens Reports 2,
84-91, 2000
Endothelin
und Atherosklerose. Kausale Bedeutung und therapeutische
Implikationen
M. Barton
Kardiovask
Med 3,
13-18, 2000
Endothelin
in atherosclerosis: importance of risk factors and therapeutic
implications
L.V. d'Uscio, M. Barton, S. Shaw, T.F. Lüscher
J
Cardiovasc Pharmacol 35
(4 suppl 2), S55-S59, 2000
Inverse
regulation of endothelin-1 and nitric oxide metabolites in tissue
with aging: implications
for the age-dependent increase of cardiorenal
disease
M. Barton, T. Lattmann, L.V. d'Uscio, T.F. Lüscher, S.
Shaw
J
Cardiovasc Pharmacol 36
(Suppl.1), S153-S156, 2000
Endothelin
regulates angiotensin-converting enzyme in the mouse
kidney
M. Barton, R. Carmona, J.E. Krieger, W. Göettsch, H. Morawietz,
L.V. d'Uscio, T. Lattmann, T.F. Lüscher, S. Shaw
J
Cardiovasc Pharmacol 36
(Suppl.1), S244-S247, 2000
1999
Endothelin
antagonists for hypertension and renal disease
M. Barton, T.F. Lüscher
Curr
Opin Nephrol Hypertens 8,
549-556, 1999
Endothelial
dysfunction in acute renal faiulre: role of circulating and tissue
endothelin-1
F. Ruschitzka, S. Shaw, D. Gygi, G. Noll, M. Barton, T.F.
Luscher
J
Am Soc Nephrol 10,
953-962, 1999
Endothelial dysfunction in the aorta of transgenic
rats harboring the mouse ren-2 gene
U.A. Arnet, D. Novosel, M. Barton, G. Noll, D. Ganten, T.F.
Lüscher
Endothelium
6,
175-184, 1999
Estrogen
and vascular resistance
M. Barton, T.F. Lüscher
Curr
Opin Endocrinol Diabet 6,
218-224, 1999
Vascular effects of estrogens: rapid actions, novel
mechanisms, and potential therapeutic
implications
M. Barton
Acta
Pharmacol Sin 20,
682-690, 1999
Endothelin
in heart failure
G. Sutsch, M. Barton
Curr
Hypertens Reports 1,
62-68, 1999
Vascular
effect of estrogen
E.
Wight, M. Barton, E. Espinosa, T. Luscher.
In:
Menopause and the Heart (T.B.
Clarkson, P. Collins, Eds), Taylor & Francis, Philadelphia; 1,
1-7, 1999
1998
Endothelin
ETA
receptor blockade restores NO-mediated endothelial function and
inhibits atherosclerosis in apolipoprotein E-deficient
mice
M. Barton, C.C. Haudenschild, L.V. d`Uscio, S. Shaw, K. Münter,
T.F. Lüscher
Proc
Natl Acad Sci U.S.A. 95,
14367-14372, 1998
ETA
receptor blockade prevents increased tissue endothelin-1, vascular
hypertrophy, and endothelial dysfunction
in salt-sensitive hypertension
M. Barton, L.V. d`Uscio, S. Shaw, P. Meyer, P. Moreau, and T.F.
Lüscher
Hypertension
31,
499-504, 1998
Losartan
but not verapamil inhibits angiotensin II-induced tissue
endothelin-1 increase. Role of blood pressure
and endothelial function
L.V. d`Uscio, S. Shaw, M. Barton, T.F. Lüscher
Hypertension
31,
1305-1310, 1998
Endothelial
aging. A determinant of cardiovascular risk
M. Barton
In: Cardiovascular Aging. Physiology, Physiology, Pharmacology and
Therapeutics. IUPHAR Satellite Symposium, Nancy, France, July
23-24, 1998
Cardiovasc
Drug Rev 3,
300-311, 1998
Salt
Wars
M. Barton, T.F. Lüscher, T.J. Rabelink
Science 281,
1961, 1998
Endothelial
vasoconstrictor prostanoids, vascular reactivity, and acute renal
failure
F. Ruschitzka, S. Shaw, G. Noll, M. Barton, E. Schulz, G.A. Müller,
T.F. Lüscher
Kidney
Int 67,
S199-S201, 1998
Differential
modulation of the renal myocardial endothelin system by angiotensin
II in vivo:
effects of chronic selective ETA
receptor blockade
M. Barton, S. Shaw, L. V. d'Uscio, P. Moreau, T.F.
Lüscher
J
Cardiovasc Pharmacol 31
(Suppl 1), S265-S268, 1998
17β-Estradiol
acutely improves endothelium-dependent relaxation to bradykinin in
isolated human coronary arteries
M. Barton, J. Cremer, A. Mügge
Eur
J Pharmacol 362,
73-76, 1998
Endothelium-independent
relaxation and hyperpolarization to C-type natriuretic peptide in
porcine coronary arteries
M. Barton, J.L. Bény, L.V. d`Uscio, T. Wyss, G. Noll, T.F.
Lüscher
J
Cardiovasc Pharmacol 31,
377-383, 1998
1997
Biology of the endothelium
T.F. Lüscher, M. Barton
Clin
Cardiol 20
(Suppl. II), 3-10, 1997
Angiotensin
II increases vascular and renal endothelin-1 and functional
endothelin converting enzyme activity in vivo:
role of ETA
receptors for endothelin regulation
M. Barton, S. Shaw, L.V. d`Uscio, P. Moreau, T.F.
Lüscher
Biochem
Biophys Res Commun 238,
861-865, 1997
Anatomic heterogeneity of vascular aging. Role of
nitric oxide and endothelin
M. Barton, F. Cosentino, R.P. Brandes, P. Moreau, S. Shaw, T.F.
Lüscher
Hypertension
30,
817-824, 1997
Structure
and function of small arteries in salt-induced hypertension:
effects of chronic endothelin-subtype-A-receptor
blockade
L.V. d'Uscio, M. Barton, S. Shaw, P. Moreau, T.F.
Lüscher
Hypertension
30,
905-911, 1997
Angiotensin
II increases tissue endothelin and induces vascular hypertrophy:
reversal by ETA-receptor
antagonist
P. Moreau, L. V. d'Uscio, S. Shaw, H. Takase, M. Barton, T.F.
Lüscher
Circulation
96,
1593-1597, 1997
Effects
of chronic ETA-receptor
blockade in angiotensin II-induced hypertension
L.V. d`Uscio, P. Moreau, S. Shaw, H. Takase, M. Barton, T.F.
Lüscher
Hypertension
29,
435-441, 1997
Endothelial-derived
superoxide anions in pig coronary arteries: evidence from lucigenin
chemiluminescence
and histochemical techniques
R.P. Brandes, M. Barton, K.M.H. Philippens, G. Schweitzer, A.
Mügge
J
Physiol (Lond) 500,
331-342, 1997
The
endothelium as therapeutic target for atherosclerosis. Importance
of ACE inhibition and cholesterol lowering
M. Barton, T.F. Lüscher
Thoraxcenter J 9,
12-19, 1997
Anatomic
heterogeneity of vascular aging. Role of nitric oxide and
endothelin
M. Barton, F. Cosentino, R.P. Brandes, P. Moreau, S. Shaw, T.F.
Lüscher
Hypertension
30,
817-824, 1997
Contractile
responses to histamine, serotonin, and angiotensin II are impaired
by 17β-estradiol
in human internal mammary arteries in vitro
A. Mügge, M. Barton, H.G. Fieguth, M. Riedel
Pharmacology
54,
162-168, 1997
Gefässprotektion
durch Oestrogene. Wirkungen in vitro und in vivo - Mechanismen und
klinische Implikationen
M. Barton, E. Wright, D.D. Do, Z. Yang, E. Espinosa, U. Arnet, T.F.
Lüscher
Schweiz
Rundsch Med (PRAXIS) 86,
129-137, 1997
1996
17β-Oestradiol
inhibits growth of human vascular smooth muscle: similar effects in
cells from females and males
Z. Yang, D.D. Do, E. Espinosa, M. Barton, A. Arnet, T. F.
Lüscher
J
Cardiovasc Pharmacol 28
(Suppl. 5), S34-S39, 1996
Wirkungen
natürlicher Oestrogene auf die Gefässwand: Molekulare Mechanismen
und klinische Implikationen
T.F. Lüscher, M. Barton, E. Wight, E. Espinosa, Z.
Yang
Schweiz
Med Wschr 126,
1748-1755, 1996
Effect
of age on kinetics of nitric oxide release in rat aorta and
pulmonary artery
M.R. Tschudi, M. Barton, N.A. Bersinger, P. Moreau, F. Cosentino,
G. Noll, T. Malinski, T.F. Lüscher
J
Clin Invest 98,
899-905, 1996
1993
Different
vascular reactivity of human internal mammary and inferior
epigastric arteries in vitro
A. Mügge, M. Barton, J. Cremer, R. Frombach, P.R.
Lichtlen
Ann
Thorac Surg 56,
1085-1089, 1993
Endothelium-independent relaxation by 17β-oestradiol
of human coronary arteries in vitro
A.
Mügge, M. Riedel, M. Barton, M. Kuhn, P.R.
Lichtlen
Cardiovasc
Res 27,
1939-1942, 1993
Estrogen
dilates human coronary arteries in vitro by an increase in cyclic
GMP and cyclic AMP smooth muscle content
A. Mügge, M. Riedel, M. Barton, M. Kuhn, P.R.
Lichtlen
Eur Heart J 14,
16, 1993
1992
Comparison
of endothelium-dependent and endothelium-independent relaxations in
human internal thoracic and inferior epigastric arteries in
vitro
A. Mügge, J. Cremer, M.R. Schulze, M. Barton, P.R.
Lichtlen
Circulation 86,
832, 1992